QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:LIXT

Lixte Biotechnology - LIXT News Today

$0.79
+0.03 (+3.96%)
(As of 01/31/2023 05:19 PM ET)
Add
Compare
Today's Range
$0.75
$0.80
50-Day Range
$0.48
$0.77
52-Week Range
$0.43
$4.95
Volume
56,707 shs
Average Volume
62,955 shs
Market Capitalization
$13.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Get Lixte Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.



LIXT Media Mentions By Week

LIXT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LIXT
News Sentiment

0.57

0.72

Average
Medical
News Sentiment

LIXT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LIXT Articles
This Week

4

0

LIXT Articles
Average Week

SourceHeadline
marketwatch.com logoGlobal Neurometabolic Disorders Market Size Growth Rate Analysis 2023 by Market Overview, Segments, Regions, Market Share and Forecast to 2028
marketwatch.com - January 26 at 1:26 AM
seekingalpha.com logoLIXT Lixte Biotechnology Holdings, Inc.
seekingalpha.com - January 25 at 3:25 PM
MarketBeat logoLixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Decrease in Short Interest
americanbankingnews.com - January 24 at 6:50 AM
marketwatch.com logoNeurometabolic Disorders Market Latest Trends, Industry Size and Future Prospects 2028
marketwatch.com - January 12 at 10:01 PM
marketwatch.com logoGaucher Disease Drugs Market Set to High Latest Developments, Growth Prospects 2023-2027 with Future Trends and Share Analysis
marketwatch.com - January 4 at 9:09 AM
marketwatch.com logoNeurometabolic Disorders Market Analysis Report 2023 Along with Statistics Figures, Forecasts till 2028
marketwatch.com - December 22 at 5:27 PM
finance.yahoo.com logoLIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference
finance.yahoo.com - November 30 at 12:13 PM
marketwatch.com logoNeurometabolic Disorders Market 2023 : Opportunities in Future, Business Growth Analysis by Top Countries Data and Industry Players by 2028
marketwatch.com - November 25 at 11:39 PM
seekingalpha.com logoPDS Biotech surges 22% as drug shows response in cervical cancer patients in phase 2 trial
seekingalpha.com - November 16 at 9:36 PM
finance.yahoo.com logoLIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
finance.yahoo.com - October 13 at 1:26 PM
finance.yahoo.com logoLIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS
finance.yahoo.com - June 21 at 11:30 AM
finance.yahoo.com logoLIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS
finance.yahoo.com - June 15 at 9:28 AM
finance.yahoo.com logoLixte Biotechnology Holdings, Inc. (LIXT)
finance.yahoo.com - June 14 at 9:00 PM
finance.yahoo.com logoWallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering
finance.yahoo.com - April 14 at 7:30 PM
finance.yahoo.com logoLIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market
finance.yahoo.com - April 14 at 7:30 PM
finance.yahoo.com logoWallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)
finance.yahoo.com - April 13 at 12:53 PM
finance.yahoo.com logoWestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)
finance.yahoo.com - April 13 at 12:53 PM
finance.yahoo.com logoHealthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers
finance.yahoo.com - April 13 at 12:53 PM
finance.yahoo.com logoWe're Keeping An Eye On Lixte Biotechnology Holdings' (NASDAQ:LIXT) Cash Burn Rate
finance.yahoo.com - April 13 at 12:53 PM
seekingalpha.com logoLIXTE Biotechnology stock shoots on $5.8M direct offering priced ATM
seekingalpha.com - April 12 at 4:36 PM
finance.yahoo.com logoLIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
finance.yahoo.com - April 12 at 4:36 PM
investorplace.com logoWhy Is Lixte Biotechnology (LIXT) Stock Up Today?
investorplace.com - April 12 at 1:06 PM
msn.com logoLixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers
msn.com - April 12 at 11:36 AM
morningstar.com logoThinking about buying stock in Lixte Biotechnology, Hoth Therapeutics, Ocugen, Bilibili, or Sunshine Biopharma?
morningstar.com - April 12 at 11:36 AM
seekingalpha.com logoLixte Biotech gains on anti-cancer activity of lead asset
seekingalpha.com - April 12 at 11:36 AM
finance.yahoo.com logoLIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations
finance.yahoo.com - April 12 at 11:36 AM
finance.yahoo.com logoInactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy
finance.yahoo.com - March 22 at 12:37 PM
finance.yahoo.com logoLIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference
finance.yahoo.com - March 16 at 10:32 AM
nasdaq.com logoLixte Biotechnology Holdings, Inc. Common Stock (LIXT)
nasdaq.com - January 22 at 7:38 PM
nasdaq.com logoLixte Biotechnology Holdings Inc Shares Close the Week 21.6% Lower - Weekly Wrap
nasdaq.com - January 18 at 9:00 PM
seekingalpha.com logoLixte Biotech files first patent application for LB-100 combination therapy in cancer
seekingalpha.com - January 12 at 11:25 AM
finance.yahoo.com logoLixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100
finance.yahoo.com - January 12 at 11:25 AM
seekingalpha.com logoLixte Biotechnology, Mainz Biomed lead healthcare gainers, Annexon, Hoth among losers
seekingalpha.com - January 7 at 7:29 AM
msn.com logoSee Why Lixte Biotech Shares Trading At Over 100%?
msn.com - January 5 at 3:24 PM
msn.com logoLixte Biotechnology Stock Surges on Positive Data
msn.com - January 5 at 3:24 PM
seekingalpha.com logoLixte Biotechnology soars after pre-clinical research supporting its lead asset
seekingalpha.com - January 5 at 10:24 AM
marketwatch.com logoLixte Biotechnology Shares Soar in Premarket on Positive Data
marketwatch.com - January 5 at 10:24 AM
finance.yahoo.com logoLixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
finance.yahoo.com - January 5 at 10:24 AM
benzinga.com logoLixte Biotech Holdings Shares Resume Trading; Up 22%
benzinga.com - December 10 at 8:42 PM
finance.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS
finance.yahoo.com - November 22 at 9:41 AM
finance.yahoo.com logoLixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
finance.yahoo.com - October 20 at 3:20 PM
finance.yahoo.com logoLixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
finance.yahoo.com - October 13 at 9:47 AM
nasdaq.com logoBullish insiders at Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) loaded up on US$1.3m of stock earlier this year
nasdaq.com - September 26 at 1:01 PM
finance.yahoo.com logoWe Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
finance.yahoo.com - September 24 at 1:41 PM
nasdaq.com logoLixte Biotechnology Holdings Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Mover
nasdaq.com - September 22 at 9:49 AM
finance.yahoo.com logoLixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
finance.yahoo.com - August 17 at 5:00 PM
finance.yahoo.com logoLixte's LB-100 Blocks Behavioral Sensitization In Animal Models
finance.yahoo.com - August 17 at 5:00 PM
barrons.com logoLixte Biotechnology Holdings Inc.
barrons.com - August 8 at 11:44 PM
msn.com logoLixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer
msn.com - August 3 at 4:10 PM
marketwatch.com logoLixte Biotechnology Shares Rise 31% on Positive Data for Lung Cancer Treatment
marketwatch.com - August 3 at 4:10 PM
Get Lixte Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:LIXT) was last updated on 1/31/2023 by MarketBeat.com Staff